

NCI DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD) FUNDING OPPORTUNITIES FOR EARLY PHASE THERAPEUTIC CLINICAL TRIALS

Lori Henderson, PhD.
Chief, Clinical Grants and Contracts Branch
Cancer Therapy Evaluation Program, DCTD

Investigator-Initiated Funding Opportunities

(1) PAR-21-033: NCI Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

- ❖ Supports research that proposes to implement Phase 0, I, or II trials on cancer-targeted diagnostic and therapeutic interventions relevant to DCTD program areas
- ❖ Applicable to a broad range of clinical investigations to improve the diagnosis and treatment of cancer in areas of common and unmet need.
- ❖ Examples include studies to determine maximum dose, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of *novel anticancer drugs, biologics, immunotherapeutic agents, adoptive cell therapies, and drug combinations*
- ❖ Budget limited to \$499,999 in direct costs per year for up to 5 years

Investigator-Initiated Opportunities (cont.)

(2) PAR-20-292: NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

- ❖ Supports high risk, potentially breakthrough, preclinical and early phase clinical research in cancer treatment and diagnosis
- ❖ Examples of research include:
 - Exploratory, Phase I, or small Phase II trials that *test new or repurposed agents, biologics, or combinations of interventions* to:
 - ✓ Treat common or rare cancers
 - ✓ Reduce cancer therapy-related toxicity
 - ✓ Enhance the effectiveness of immune therapies
 - ✓ Reduce cancer health disparities
 - Canine trials to facilitate the development of new therapies for cancer
- ❖ Budget for these 2-year projects may not exceed \$275,000 in direct costs with no more than \$200,000 in any single year.

Opportunities for Clinical Research Collaborations

(3) PAR-20-077: NCI Investigator-Initiated Program Project Applications (P01 Clinical Trial Optional)

- ❖ Supports an integrated, collaborative research program with a well-defined, central research focus in any broad areas of cancer research – e.g., cancer diagnosis and treatment
- ❖ Research may include a *combination of basic, translational, and clinical studies involving Phase I and II clinical trials in these areas*
- ❖ Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core.
- ❖ Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Clinical Research Collaborations (cont.)

(4) PAR-21-343 Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

- ❖ Supports applications proposing impactful, innovative collaborative research between extramural researchers and the NIH intramural investigators at the NIH Clinical Center
- ❖ Collaborative projects must align with NIH efforts to enhance the translation of discoveries into clinical applications to improve health
- ❖ Areas of Interests to NCI include: (1) Accelerating clinical evaluation of safe, effective, and durable therapeutic interventions, (2) Collaborating with clinicians in the NCI Center for Cancer Research on *clinical protocols, unique pharmaceutical agents and/or other modes of therapy, or extraordinarily rare diseases*
- ❖ Information about the NCI intramural investigators and their research interests can be found at <https://ccr.cancer.gov/>.

Take Home Message

- Visit the **Division of Cancer Treatment and Diagnosis** website to learn more about the various NCI program goals, and research priorities
- Consult the scientific contact liaison listed on individual Funding Opportunity Announcements
- Contact Program Staff in the **Clinical Grants and Contracts Branch** of the Cancer Therapy Evaluation Program at NCI for more information and guidance on cancer therapy trials funded via grants and cooperative agreements

Thank you for your attention



Thank you for your attention



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol